IARC 2017 is coming up very soon! 

In one week we will be opening our International Ataxia Research Conference in Pisa - Friedreichsaataxianews will be covering the event and has published their third article about this big event to come! You can the article here.

Posted: 20/09/2017

IARC 2017 is opening in a week! 

In one week we will be opening our International Ataxia Research Conference in Pisa - Friedreichsaataxianews will be covering the event and has published their second article about this big event to come! You can the article including the interview of Ataxia UK's Head of Research Julie Greenfield and CEO Sue Millman here.

Posted: 19/09/2017

SMi Orphan Drugs Europe in London - Ataxia UK is taking part!

The 7th annual Orphan Drugs Europe conference organised by SMI will take place in London on the 18th -19th October 2017. Ataxia UK will be taking part in the conference, presenting an overview of research strategy and activities of the charity. Dr Julie Vallortigara, Research Officer at Ataxia UK, has been interviewed as part of the series of speakers interviews done by SMi; you can find the interview here. To find out about this conference, please visit their website here.

Posted: 07/09/2017

Jupiter Orphan Therapeutics receives orphan drug designation for its trans-resveratrol product JOTROL for treatment of Freidreich's ataxia 

Jupiter Orphan Therapeutics has announced that it has received notification from the Food and Drug Administration (FDA) that its orphan drug designation request for its trans-resveratrol has been granted. You can read more here. 

Posted: 25/08/2017

IARC 2017 is coming up! 

In one month we will be opening our International Ataxia Research Conference in Pisa - Friedreichsaataxianews will be covering the event and has published their first article about this big event to come! You can the article here.

Posted: 24/08/2017

Reata pharmaceuticals received orphan drug designation for Omaveloxolone for the treatment of Friedreich's ataxia, and announces a large investment for drug development 

Reata Pharmaceuticals sold some of it shares, generating sales of approximately $115.9 million to be used to support the clinical development of the company's pipeline, including omaveloxolone, its lead investigative product for Friedreich's ataxia. You can read more about the investment here and the orphan drug designation in this press release.

Posted: 08/08/2017